nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—Protein Kinase Inhibitors—Vemurafenib—melanoma	0.378	1	CiPCiCtD
Sunitinib—kidney cancer—melanoma	0.223	1	CtDrD
Sunitinib—MAP2K2—melanoma	0.0508	0.237	CbGaD
Sunitinib—PTK2B—melanoma	0.0385	0.179	CbGaD
Sunitinib—MAP2K1—melanoma	0.0385	0.179	CbGaD
Sunitinib—FLT1—melanoma	0.0274	0.128	CbGaD
Sunitinib—PDGFRA—melanoma	0.0221	0.103	CbGaD
Sunitinib—KDR—melanoma	0.0172	0.0802	CbGaD
Sunitinib—KIT—melanoma	0.0162	0.0756	CbGaD
Sunitinib—ABCG2—Vemurafenib—melanoma	0.00823	0.242	CbGbCtD
Sunitinib—ABCG2—Dactinomycin—melanoma	0.00547	0.161	CbGbCtD
Sunitinib—ABCB1—melanoma	0.00374	0.0174	CbGaD
Sunitinib—CYP3A4—Temozolomide—melanoma	0.00324	0.0954	CbGbCtD
Sunitinib—ABCC2—Docetaxel—melanoma	0.00312	0.0919	CbGbCtD
Sunitinib—ABCG2—Docetaxel—melanoma	0.00282	0.0831	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.00209	0.0613	CbGbCtD
Sunitinib—CYP3A7—Docetaxel—melanoma	0.00209	0.0613	CbGbCtD
Sunitinib—ABCB1—Dactinomycin—melanoma	0.00197	0.058	CbGbCtD
Sunitinib—CYP3A4—Vemurafenib—melanoma	0.00178	0.0523	CbGbCtD
Sunitinib—CYP3A5—Docetaxel—melanoma	0.00156	0.046	CbGbCtD
Sunitinib—ABCB1—Docetaxel—melanoma	0.00102	0.0299	CbGbCtD
Sunitinib—CYP3A4—Docetaxel—melanoma	0.00061	0.0179	CbGbCtD
Sunitinib—Procainamide—SCN11A—melanoma	0.000528	0.493	CrCbGaD
Sunitinib—CHEK2—Paclitaxel—Docetaxel—melanoma	0.00047	1	CbGdCrCtD
Sunitinib—Metoclopramide—CYP17A1—melanoma	0.000345	0.322	CrCbGaD
Sunitinib—Procainamide—SCN10A—melanoma	0.000199	0.185	CrCbGaD
Sunitinib—CSNK1A1—skin of body—melanoma	8.68e-05	0.00245	CbGeAlD
Sunitinib—MAP3K7—retina—melanoma	8.68e-05	0.00245	CbGeAlD
Sunitinib—TBK1—eye—melanoma	8.65e-05	0.00244	CbGeAlD
Sunitinib—SGK3—head—melanoma	8.65e-05	0.00244	CbGeAlD
Sunitinib—TYK2—eye—melanoma	8.6e-05	0.00243	CbGeAlD
Sunitinib—ICK—head—melanoma	8.57e-05	0.00242	CbGeAlD
Sunitinib—TYK2—retina—melanoma	8.52e-05	0.0024	CbGeAlD
Sunitinib—MERTK—mammalian vulva—melanoma	8.46e-05	0.00239	CbGeAlD
Sunitinib—RPS6KB1—eye—melanoma	8.33e-05	0.00235	CbGeAlD
Sunitinib—MAP4K4—mammalian vulva—melanoma	8.31e-05	0.00234	CbGeAlD
Sunitinib—KDR—neck—melanoma	8.28e-05	0.00234	CbGeAlD
Sunitinib—NUAK1—head—melanoma	8.28e-05	0.00234	CbGeAlD
Sunitinib—RPS6KB1—retina—melanoma	8.25e-05	0.00233	CbGeAlD
Sunitinib—NUAK2—mammalian vulva—melanoma	8.25e-05	0.00233	CbGeAlD
Sunitinib—AXL—eye—melanoma	8.24e-05	0.00233	CbGeAlD
Sunitinib—PRKAA2—lymph node—melanoma	8.23e-05	0.00232	CbGeAlD
Sunitinib—INSR—head—melanoma	8.21e-05	0.00232	CbGeAlD
Sunitinib—SNRK—head—melanoma	8.21e-05	0.00232	CbGeAlD
Sunitinib—MAP3K12—mammalian vulva—melanoma	8.19e-05	0.00231	CbGeAlD
Sunitinib—AXL—retina—melanoma	8.17e-05	0.0023	CbGeAlD
Sunitinib—STK38—head—melanoma	8.08e-05	0.00228	CbGeAlD
Sunitinib—RPS6KA2—head—melanoma	8.08e-05	0.00228	CbGeAlD
Sunitinib—RPS6KA3—mammalian vulva—melanoma	8.08e-05	0.00228	CbGeAlD
Sunitinib—CSNK1E—skin of body—melanoma	8.04e-05	0.00227	CbGeAlD
Sunitinib—AURKC—head—melanoma	8.02e-05	0.00226	CbGeAlD
Sunitinib—CSNK1G2—head—melanoma	7.96e-05	0.00225	CbGeAlD
Sunitinib—PKN1—head—melanoma	7.96e-05	0.00225	CbGeAlD
Sunitinib—STK17B—lymph node—melanoma	7.92e-05	0.00224	CbGeAlD
Sunitinib—CSNK1A1—mammalian vulva—melanoma	7.92e-05	0.00223	CbGeAlD
Sunitinib—CLK1—mammalian vulva—melanoma	7.87e-05	0.00222	CbGeAlD
Sunitinib—FGFR2—eye—melanoma	7.86e-05	0.00222	CbGeAlD
Sunitinib—PRPF4—head—melanoma	7.84e-05	0.00221	CbGeAlD
Sunitinib—MAP2K2—skin of body—melanoma	7.74e-05	0.00219	CbGeAlD
Sunitinib—PRPF4B—head—melanoma	7.73e-05	0.00218	CbGeAlD
Sunitinib—LRRK2—mammalian vulva—melanoma	7.65e-05	0.00216	CbGeAlD
Sunitinib—STK39—head—melanoma	7.62e-05	0.00215	CbGeAlD
Sunitinib—CSNK2A1—head—melanoma	7.52e-05	0.00212	CbGeAlD
Sunitinib—TYK2—skin of body—melanoma	7.48e-05	0.00211	CbGeAlD
Sunitinib—MYLK—head—melanoma	7.43e-05	0.0021	CbGeAlD
Sunitinib—KIT—neck—melanoma	7.34e-05	0.00207	CbGeAlD
Sunitinib—CSNK1E—mammalian vulva—melanoma	7.34e-05	0.00207	CbGeAlD
Sunitinib—FGFR1—mammalian vulva—melanoma	7.34e-05	0.00207	CbGeAlD
Sunitinib—STK17A—lymph node—melanoma	7.3e-05	0.00206	CbGeAlD
Sunitinib—STK4—head—melanoma	7.29e-05	0.00206	CbGeAlD
Sunitinib—FLT1—eye—melanoma	7.29e-05	0.00206	CbGeAlD
Sunitinib—IRAK4—mammalian vulva—melanoma	7.22e-05	0.00204	CbGeAlD
Sunitinib—FLT1—retina—melanoma	7.22e-05	0.00204	CbGeAlD
Sunitinib—CDK14—lymph node—melanoma	7.19e-05	0.00203	CbGeAlD
Sunitinib—AXL—skin of body—melanoma	7.17e-05	0.00202	CbGeAlD
Sunitinib—PDGFRB—neck—melanoma	7.17e-05	0.00202	CbGeAlD
Sunitinib—PHKG2—head—melanoma	7.16e-05	0.00202	CbGeAlD
Sunitinib—STK24—head—melanoma	7.12e-05	0.00201	CbGeAlD
Sunitinib—PAK3—lymph node—melanoma	7.09e-05	0.002	CbGeAlD
Sunitinib—LATS2—lymph node—melanoma	7.09e-05	0.002	CbGeAlD
Sunitinib—CDK16—lymph node—melanoma	7.09e-05	0.002	CbGeAlD
Sunitinib—ULK3—mammalian vulva—melanoma	7.06e-05	0.00199	CbGeAlD
Sunitinib—MAP2K2—mammalian vulva—melanoma	7.06e-05	0.00199	CbGeAlD
Sunitinib—RPS6KA5—lymph node—melanoma	7e-05	0.00197	CbGeAlD
Sunitinib—YES1—eye—melanoma	6.96e-05	0.00196	CbGeAlD
Sunitinib—MAP3K7—mammalian vulva—melanoma	6.95e-05	0.00196	CbGeAlD
Sunitinib—STK16—head—melanoma	6.93e-05	0.00195	CbGeAlD
Sunitinib—YES1—retina—melanoma	6.9e-05	0.00195	CbGeAlD
Sunitinib—HIPK2—head—melanoma	6.89e-05	0.00194	CbGeAlD
Sunitinib—TYRO3—head—melanoma	6.89e-05	0.00194	CbGeAlD
Sunitinib—ALK—head—melanoma	6.89e-05	0.00194	CbGeAlD
Sunitinib—TAOK3—eye—melanoma	6.87e-05	0.00194	CbGeAlD
Sunitinib—TBK1—mammalian vulva—melanoma	6.87e-05	0.00194	CbGeAlD
Sunitinib—FGFR2—skin of body—melanoma	6.84e-05	0.00193	CbGeAlD
Sunitinib—TYK2—mammalian vulva—melanoma	6.82e-05	0.00192	CbGeAlD
Sunitinib—RIOK2—head—melanoma	6.82e-05	0.00192	CbGeAlD
Sunitinib—TAOK3—retina—melanoma	6.81e-05	0.00192	CbGeAlD
Sunitinib—JAK2—skin of body—melanoma	6.8e-05	0.00192	CbGeAlD
Sunitinib—MAP3K19—head—melanoma	6.75e-05	0.0019	CbGeAlD
Sunitinib—CLK4—lymph node—melanoma	6.74e-05	0.0019	CbGeAlD
Sunitinib—IRAK1—mammalian vulva—melanoma	6.73e-05	0.0019	CbGeAlD
Sunitinib—FYN—skin of body—melanoma	6.71e-05	0.00189	CbGeAlD
Sunitinib—ITK—lymph node—melanoma	6.66e-05	0.00188	CbGeAlD
Sunitinib—SBK1—lymph node—melanoma	6.66e-05	0.00188	CbGeAlD
Sunitinib—DAPK3—head—melanoma	6.62e-05	0.00187	CbGeAlD
Sunitinib—RPS6KB1—mammalian vulva—melanoma	6.61e-05	0.00186	CbGeAlD
Sunitinib—BLK—lymph node—melanoma	6.58e-05	0.00186	CbGeAlD
Sunitinib—FGR—mammalian vulva—melanoma	6.57e-05	0.00185	CbGeAlD
Sunitinib—MAP3K3—skin of body—melanoma	6.56e-05	0.00185	CbGeAlD
Sunitinib—CLK2—head—melanoma	6.56e-05	0.00185	CbGeAlD
Sunitinib—AXL—mammalian vulva—melanoma	6.54e-05	0.00185	CbGeAlD
Sunitinib—PHKG1—lymph node—melanoma	6.5e-05	0.00184	CbGeAlD
Sunitinib—DAPK1—lymph node—melanoma	6.5e-05	0.00184	CbGeAlD
Sunitinib—STK3—head—melanoma	6.44e-05	0.00182	CbGeAlD
Sunitinib—ROCK1—head—melanoma	6.36e-05	0.00179	CbGeAlD
Sunitinib—STK11—lymph node—melanoma	6.3e-05	0.00178	CbGeAlD
Sunitinib—BRD4—lymph node—melanoma	6.3e-05	0.00178	CbGeAlD
Sunitinib—SLK—mammalian vulva—melanoma	6.29e-05	0.00178	CbGeAlD
Sunitinib—EPHB6—skin of body—melanoma	6.27e-05	0.00177	CbGeAlD
Sunitinib—RIOK1—lymph node—melanoma	6.24e-05	0.00176	CbGeAlD
Sunitinib—RPS6KA1—lymph node—melanoma	6.24e-05	0.00176	CbGeAlD
Sunitinib—JAK2—mammalian vulva—melanoma	6.21e-05	0.00175	CbGeAlD
Sunitinib—DYRK1A—head—melanoma	6.2e-05	0.00175	CbGeAlD
Sunitinib—KDR—eye—melanoma	6.16e-05	0.00174	CbGeAlD
Sunitinib—FYN—mammalian vulva—melanoma	6.12e-05	0.00173	CbGeAlD
Sunitinib—MARK2—lymph node—melanoma	6.12e-05	0.00173	CbGeAlD
Sunitinib—TNIK—lymph node—melanoma	6.12e-05	0.00173	CbGeAlD
Sunitinib—KDR—retina—melanoma	6.11e-05	0.00172	CbGeAlD
Sunitinib—SGK3—lymph node—melanoma	6.06e-05	0.00171	CbGeAlD
Sunitinib—MERTK—head—melanoma	6.05e-05	0.00171	CbGeAlD
Sunitinib—CSF1R—eye—melanoma	6.01e-05	0.0017	CbGeAlD
Sunitinib—ICK—lymph node—melanoma	6e-05	0.00169	CbGeAlD
Sunitinib—MAP4K5—mammalian vulva—melanoma	5.98e-05	0.00169	CbGeAlD
Sunitinib—MAP3K3—mammalian vulva—melanoma	5.98e-05	0.00169	CbGeAlD
Sunitinib—MAP4K4—head—melanoma	5.94e-05	0.00168	CbGeAlD
Sunitinib—MAP3K12—head—melanoma	5.86e-05	0.00165	CbGeAlD
Sunitinib—CHEK2—lymph node—melanoma	5.8e-05	0.00164	CbGeAlD
Sunitinib—NUAK1—lymph node—melanoma	5.8e-05	0.00164	CbGeAlD
Sunitinib—FLT1—mammalian vulva—melanoma	5.78e-05	0.00163	CbGeAlD
Sunitinib—RPS6KA3—head—melanoma	5.78e-05	0.00163	CbGeAlD
Sunitinib—INSR—lymph node—melanoma	5.75e-05	0.00162	CbGeAlD
Sunitinib—SNRK—lymph node—melanoma	5.75e-05	0.00162	CbGeAlD
Sunitinib—OXSR1—lymph node—melanoma	5.75e-05	0.00162	CbGeAlD
Sunitinib—MAP2K1—head—melanoma	5.74e-05	0.00162	CbGeAlD
Sunitinib—EPHB6—mammalian vulva—melanoma	5.72e-05	0.00161	CbGeAlD
Sunitinib—CSNK1A1—head—melanoma	5.66e-05	0.0016	CbGeAlD
Sunitinib—STK38—lymph node—melanoma	5.66e-05	0.0016	CbGeAlD
Sunitinib—RPS6KA2—lymph node—melanoma	5.66e-05	0.0016	CbGeAlD
Sunitinib—CLK1—head—melanoma	5.63e-05	0.00159	CbGeAlD
Sunitinib—AURKC—lymph node—melanoma	5.61e-05	0.00158	CbGeAlD
Sunitinib—PKN1—lymph node—melanoma	5.57e-05	0.00157	CbGeAlD
Sunitinib—CSNK1G2—lymph node—melanoma	5.57e-05	0.00157	CbGeAlD
Sunitinib—BMP2K—head—melanoma	5.52e-05	0.00156	CbGeAlD
Sunitinib—CAMK2G—head—melanoma	5.52e-05	0.00156	CbGeAlD
Sunitinib—YES1—mammalian vulva—melanoma	5.52e-05	0.00156	CbGeAlD
Sunitinib—PRPF4—lymph node—melanoma	5.49e-05	0.00155	CbGeAlD
Sunitinib—LRRK2—head—melanoma	5.47e-05	0.00154	CbGeAlD
Sunitinib—STK10—mammalian vulva—melanoma	5.47e-05	0.00154	CbGeAlD
Sunitinib—TAOK3—mammalian vulva—melanoma	5.45e-05	0.00154	CbGeAlD
Sunitinib—PRPF4B—lymph node—melanoma	5.41e-05	0.00153	CbGeAlD
Sunitinib—Hot flush—Docetaxel—melanoma	5.4e-05	0.0015	CcSEcCtD
Sunitinib—PRKAA1—head—melanoma	5.4e-05	0.00152	CbGeAlD
Sunitinib—Flushing—Dactinomycin—melanoma	5.39e-05	0.00149	CcSEcCtD
Sunitinib—Hypersensitivity—Vemurafenib—melanoma	5.38e-05	0.00149	CcSEcCtD
Sunitinib—Oedema peripheral—Carmustine—melanoma	5.36e-05	0.00148	CcSEcCtD
Sunitinib—Menopausal symptoms—Docetaxel—melanoma	5.35e-05	0.00148	CcSEcCtD
Sunitinib—Connective tissue disorder—Carmustine—melanoma	5.34e-05	0.00148	CcSEcCtD
Sunitinib—STK39—lymph node—melanoma	5.34e-05	0.00151	CbGeAlD
Sunitinib—PTK2B—head—melanoma	5.34e-05	0.00151	CbGeAlD
Sunitinib—PDGFRB—eye—melanoma	5.33e-05	0.0015	CbGeAlD
Sunitinib—FLT4—head—melanoma	5.32e-05	0.0015	CbGeAlD
Sunitinib—Renal impairment—Docetaxel—melanoma	5.31e-05	0.00147	CcSEcCtD
Sunitinib—Dermatitis bullous—Docetaxel—melanoma	5.29e-05	0.00146	CcSEcCtD
Sunitinib—Haemoglobin—Temozolomide—melanoma	5.28e-05	0.00146	CcSEcCtD
Sunitinib—CSNK2A1—lymph node—melanoma	5.27e-05	0.00149	CbGeAlD
Sunitinib—Haemorrhage—Temozolomide—melanoma	5.26e-05	0.00146	CcSEcCtD
Sunitinib—Hepatitis—Temozolomide—melanoma	5.26e-05	0.00146	CcSEcCtD
Sunitinib—CSNK1E—head—melanoma	5.25e-05	0.00148	CbGeAlD
Sunitinib—Asthenia—Vemurafenib—melanoma	5.24e-05	0.00145	CcSEcCtD
Sunitinib—CSF1R—skin of body—melanoma	5.23e-05	0.00148	CbGeAlD
Sunitinib—Hypoaesthesia—Temozolomide—melanoma	5.23e-05	0.00145	CcSEcCtD
Sunitinib—Chills—Dactinomycin—melanoma	5.21e-05	0.00144	CcSEcCtD
Sunitinib—MYLK—lymph node—melanoma	5.2e-05	0.00147	CbGeAlD
Sunitinib—Urinary tract disorder—Temozolomide—melanoma	5.19e-05	0.00144	CcSEcCtD
Sunitinib—Oedema peripheral—Temozolomide—melanoma	5.18e-05	0.00143	CcSEcCtD
Sunitinib—Cardiac failure—Docetaxel—melanoma	5.18e-05	0.00143	CcSEcCtD
Sunitinib—Pruritus—Vemurafenib—melanoma	5.17e-05	0.00143	CcSEcCtD
Sunitinib—IRAK4—head—melanoma	5.17e-05	0.00146	CbGeAlD
Sunitinib—Connective tissue disorder—Temozolomide—melanoma	5.16e-05	0.00143	CcSEcCtD
Sunitinib—Urethral disorder—Temozolomide—melanoma	5.15e-05	0.00143	CcSEcCtD
Sunitinib—PLK4—lymph node—melanoma	5.14e-05	0.00145	CbGeAlD
Sunitinib—Alopecia—Dactinomycin—melanoma	5.13e-05	0.00142	CcSEcCtD
Sunitinib—STK4—lymph node—melanoma	5.1e-05	0.00144	CbGeAlD
Sunitinib—Eye disorder—Carmustine—melanoma	5.08e-05	0.00141	CcSEcCtD
Sunitinib—Hyponatraemia—Docetaxel—melanoma	5.07e-05	0.0014	CcSEcCtD
Sunitinib—Erythema—Dactinomycin—melanoma	5.06e-05	0.0014	CcSEcCtD
Sunitinib—ULK3—head—melanoma	5.05e-05	0.00143	CbGeAlD
Sunitinib—MAP2K2—head—melanoma	5.05e-05	0.00143	CbGeAlD
Sunitinib—Pain in extremity—Docetaxel—melanoma	5.05e-05	0.0014	CcSEcCtD
Sunitinib—Flushing—Carmustine—melanoma	5.05e-05	0.0014	CcSEcCtD
Sunitinib—MAP3K2—head—melanoma	5.02e-05	0.00142	CbGeAlD
Sunitinib—PHKG2—lymph node—melanoma	5.01e-05	0.00141	CbGeAlD
Sunitinib—Anaemia—Bleomycin—melanoma	5.01e-05	0.00139	CcSEcCtD
Sunitinib—Diarrhoea—Vemurafenib—melanoma	5e-05	0.00138	CcSEcCtD
Sunitinib—STK24—lymph node—melanoma	4.99e-05	0.00141	CbGeAlD
Sunitinib—Erythema multiforme—Temozolomide—melanoma	4.97e-05	0.00138	CcSEcCtD
Sunitinib—DAPK2—lymph node—melanoma	4.93e-05	0.00139	CbGeAlD
Sunitinib—TBK1—head—melanoma	4.91e-05	0.00139	CbGeAlD
Sunitinib—Eye disorder—Temozolomide—melanoma	4.91e-05	0.00136	CcSEcCtD
Sunitinib—KDR—mammalian vulva—melanoma	4.89e-05	0.00138	CbGeAlD
Sunitinib—MAP2K5—mammalian vulva—melanoma	4.89e-05	0.00138	CbGeAlD
Sunitinib—TYK2—head—melanoma	4.88e-05	0.00138	CbGeAlD
Sunitinib—Cardiac disorder—Temozolomide—melanoma	4.88e-05	0.00135	CcSEcCtD
Sunitinib—Flushing—Temozolomide—melanoma	4.88e-05	0.00135	CcSEcCtD
Sunitinib—Arrhythmia—Carmustine—melanoma	4.86e-05	0.00135	CcSEcCtD
Sunitinib—Leukopenia—Bleomycin—melanoma	4.85e-05	0.00134	CcSEcCtD
Sunitinib—STK16—lymph node—melanoma	4.85e-05	0.00137	CbGeAlD
Sunitinib—Dizziness—Vemurafenib—melanoma	4.83e-05	0.00134	CcSEcCtD
Sunitinib—HIPK2—lymph node—melanoma	4.82e-05	0.00136	CbGeAlD
Sunitinib—HIPK3—lymph node—melanoma	4.82e-05	0.00136	CbGeAlD
Sunitinib—ALK—lymph node—melanoma	4.82e-05	0.00136	CbGeAlD
Sunitinib—Alopecia—Carmustine—melanoma	4.81e-05	0.00133	CcSEcCtD
Sunitinib—RIOK2—lymph node—melanoma	4.77e-05	0.00135	CbGeAlD
Sunitinib—TNK1—lymph node—melanoma	4.77e-05	0.00135	CbGeAlD
Sunitinib—CSF1R—mammalian vulva—melanoma	4.77e-05	0.00135	CbGeAlD
Sunitinib—Angiopathy—Temozolomide—melanoma	4.77e-05	0.00132	CcSEcCtD
Sunitinib—Mental disorder—Carmustine—melanoma	4.76e-05	0.00132	CcSEcCtD
Sunitinib—KIT—skin of body—melanoma	4.75e-05	0.00134	CbGeAlD
Sunitinib—Immune system disorder—Temozolomide—melanoma	4.75e-05	0.00131	CcSEcCtD
Sunitinib—Mediastinal disorder—Temozolomide—melanoma	4.74e-05	0.00131	CcSEcCtD
Sunitinib—Malnutrition—Carmustine—melanoma	4.73e-05	0.00131	CcSEcCtD
Sunitinib—Erythema—Carmustine—melanoma	4.73e-05	0.00131	CcSEcCtD
Sunitinib—Cough—Bleomycin—melanoma	4.73e-05	0.00131	CcSEcCtD
Sunitinib—MAP4K1—lymph node—melanoma	4.73e-05	0.00133	CbGeAlD
Sunitinib—RPS6KB1—head—melanoma	4.73e-05	0.00133	CbGeAlD
Sunitinib—Chills—Temozolomide—melanoma	4.72e-05	0.00131	CcSEcCtD
Sunitinib—Dehydration—Docetaxel—melanoma	4.7e-05	0.0013	CcSEcCtD
Sunitinib—FGR—head—melanoma	4.7e-05	0.00133	CbGeAlD
Sunitinib—RET—head—melanoma	4.7e-05	0.00133	CbGeAlD
Sunitinib—AXL—head—melanoma	4.68e-05	0.00132	CbGeAlD
Sunitinib—Anaemia—Dactinomycin—melanoma	4.68e-05	0.00129	CcSEcCtD
Sunitinib—Liver function test abnormal—Docetaxel—melanoma	4.66e-05	0.00129	CcSEcCtD
Sunitinib—Vomiting—Vemurafenib—melanoma	4.65e-05	0.00129	CcSEcCtD
Sunitinib—Alopecia—Temozolomide—melanoma	4.64e-05	0.00129	CcSEcCtD
Sunitinib—PDGFRB—skin of body—melanoma	4.64e-05	0.00131	CbGeAlD
Sunitinib—DAPK3—lymph node—melanoma	4.63e-05	0.00131	CbGeAlD
Sunitinib—Dry skin—Docetaxel—melanoma	4.63e-05	0.00128	CcSEcCtD
Sunitinib—Chest pain—Bleomycin—melanoma	4.62e-05	0.00128	CcSEcCtD
Sunitinib—Myalgia—Bleomycin—melanoma	4.62e-05	0.00128	CcSEcCtD
Sunitinib—Abdominal pain upper—Docetaxel—melanoma	4.61e-05	0.00128	CcSEcCtD
Sunitinib—Rash—Vemurafenib—melanoma	4.61e-05	0.00128	CcSEcCtD
Sunitinib—Mental disorder—Temozolomide—melanoma	4.6e-05	0.00128	CcSEcCtD
Sunitinib—Dermatitis—Vemurafenib—melanoma	4.6e-05	0.00127	CcSEcCtD
Sunitinib—CLK2—lymph node—melanoma	4.59e-05	0.0013	CbGeAlD
Sunitinib—Back pain—Carmustine—melanoma	4.58e-05	0.00127	CcSEcCtD
Sunitinib—Headache—Vemurafenib—melanoma	4.58e-05	0.00127	CcSEcCtD
Sunitinib—Erythema—Temozolomide—melanoma	4.58e-05	0.00127	CcSEcCtD
Sunitinib—Malnutrition—Temozolomide—melanoma	4.58e-05	0.00127	CcSEcCtD
Sunitinib—MAP4K2—lymph node—melanoma	4.57e-05	0.00129	CbGeAlD
Sunitinib—Toxic epidermal necrolysis—Docetaxel—melanoma	4.55e-05	0.00126	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Docetaxel—melanoma	4.55e-05	0.00126	CcSEcCtD
Sunitinib—Leukopenia—Dactinomycin—melanoma	4.53e-05	0.00125	CcSEcCtD
Sunitinib—Nasopharyngitis—Docetaxel—melanoma	4.52e-05	0.00125	CcSEcCtD
Sunitinib—STK3—lymph node—melanoma	4.51e-05	0.00127	CbGeAlD
Sunitinib—Dysgeusia—Temozolomide—melanoma	4.48e-05	0.00124	CcSEcCtD
Sunitinib—FGFR2—head—melanoma	4.46e-05	0.00126	CbGeAlD
Sunitinib—Alanine aminotransferase increased—Docetaxel—melanoma	4.46e-05	0.00123	CcSEcCtD
Sunitinib—JAK2—head—melanoma	4.44e-05	0.00125	CbGeAlD
Sunitinib—Oedema—Bleomycin—melanoma	4.43e-05	0.00123	CcSEcCtD
Sunitinib—Back pain—Temozolomide—melanoma	4.43e-05	0.00123	CcSEcCtD
Sunitinib—Infection—Bleomycin—melanoma	4.4e-05	0.00122	CcSEcCtD
Sunitinib—FYN—head—melanoma	4.38e-05	0.00124	CbGeAlD
Sunitinib—Anaemia—Carmustine—melanoma	4.38e-05	0.00121	CcSEcCtD
Sunitinib—Dysphagia—Docetaxel—melanoma	4.37e-05	0.00121	CcSEcCtD
Sunitinib—DYRK1A—lymph node—melanoma	4.34e-05	0.00122	CbGeAlD
Sunitinib—Nausea—Vemurafenib—melanoma	4.34e-05	0.0012	CcSEcCtD
Sunitinib—Thrombocytopenia—Bleomycin—melanoma	4.33e-05	0.0012	CcSEcCtD
Sunitinib—KIT—mammalian vulva—melanoma	4.33e-05	0.00122	CbGeAlD
Sunitinib—Myalgia—Dactinomycin—melanoma	4.31e-05	0.00119	CcSEcCtD
Sunitinib—MAP4K5—head—melanoma	4.28e-05	0.00121	CbGeAlD
Sunitinib—MAP3K3—head—melanoma	4.28e-05	0.00121	CbGeAlD
Sunitinib—MERTK—lymph node—melanoma	4.24e-05	0.0012	CbGeAlD
Sunitinib—Leukopenia—Carmustine—melanoma	4.24e-05	0.00117	CcSEcCtD
Sunitinib—PDGFRB—mammalian vulva—melanoma	4.23e-05	0.00119	CbGeAlD
Sunitinib—Anaemia—Temozolomide—melanoma	4.23e-05	0.00117	CcSEcCtD
Sunitinib—Anorexia—Bleomycin—melanoma	4.22e-05	0.00117	CcSEcCtD
Sunitinib—Angioedema—Temozolomide—melanoma	4.18e-05	0.00116	CcSEcCtD
Sunitinib—MAP4K4—lymph node—melanoma	4.16e-05	0.00117	CbGeAlD
Sunitinib—Pancytopenia—Docetaxel—melanoma	4.15e-05	0.00115	CcSEcCtD
Sunitinib—FLT1—head—melanoma	4.14e-05	0.00117	CbGeAlD
Sunitinib—NUAK2—lymph node—melanoma	4.13e-05	0.00117	CbGeAlD
Sunitinib—Oedema—Dactinomycin—melanoma	4.13e-05	0.00114	CcSEcCtD
Sunitinib—Convulsion—Carmustine—melanoma	4.1e-05	0.00114	CcSEcCtD
Sunitinib—MAP3K12—lymph node—melanoma	4.1e-05	0.00116	CbGeAlD
Sunitinib—FLT3—lymph node—melanoma	4.1e-05	0.00116	CbGeAlD
Sunitinib—Infection—Dactinomycin—melanoma	4.1e-05	0.00114	CcSEcCtD
Sunitinib—Leukopenia—Temozolomide—melanoma	4.1e-05	0.00113	CcSEcCtD
Sunitinib—EPHB6—head—melanoma	4.09e-05	0.00115	CbGeAlD
Sunitinib—Hypertension—Carmustine—melanoma	4.09e-05	0.00113	CcSEcCtD
Sunitinib—Neutropenia—Docetaxel—melanoma	4.08e-05	0.00113	CcSEcCtD
Sunitinib—RPS6KA3—lymph node—melanoma	4.05e-05	0.00114	CbGeAlD
Sunitinib—Thrombocytopenia—Dactinomycin—melanoma	4.04e-05	0.00112	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Bleomycin—melanoma	4.03e-05	0.00112	CcSEcCtD
Sunitinib—Chest pain—Carmustine—melanoma	4.03e-05	0.00112	CcSEcCtD
Sunitinib—Myalgia—Carmustine—melanoma	4.03e-05	0.00112	CcSEcCtD
Sunitinib—MAP2K1—lymph node—melanoma	4.02e-05	0.00113	CbGeAlD
Sunitinib—Cough—Temozolomide—melanoma	3.99e-05	0.00111	CcSEcCtD
Sunitinib—Paraesthesia—Bleomycin—melanoma	3.97e-05	0.0011	CcSEcCtD
Sunitinib—CSNK1A1—lymph node—melanoma	3.97e-05	0.00112	CbGeAlD
Sunitinib—Convulsion—Temozolomide—melanoma	3.96e-05	0.0011	CcSEcCtD
Sunitinib—YES1—head—melanoma	3.95e-05	0.00112	CbGeAlD
Sunitinib—Weight decreased—Docetaxel—melanoma	3.95e-05	0.00109	CcSEcCtD
Sunitinib—Hypertension—Temozolomide—melanoma	3.95e-05	0.00109	CcSEcCtD
Sunitinib—Dyspnoea—Bleomycin—melanoma	3.95e-05	0.00109	CcSEcCtD
Sunitinib—CLK1—lymph node—melanoma	3.94e-05	0.00111	CbGeAlD
Sunitinib—Anorexia—Dactinomycin—melanoma	3.94e-05	0.00109	CcSEcCtD
Sunitinib—STK10—head—melanoma	3.92e-05	0.00111	CbGeAlD
Sunitinib—Pneumonia—Docetaxel—melanoma	3.92e-05	0.00108	CcSEcCtD
Sunitinib—TAOK3—head—melanoma	3.9e-05	0.0011	CbGeAlD
Sunitinib—Myalgia—Temozolomide—melanoma	3.9e-05	0.00108	CcSEcCtD
Sunitinib—Arthralgia—Temozolomide—melanoma	3.9e-05	0.00108	CcSEcCtD
Sunitinib—Infestation NOS—Docetaxel—melanoma	3.89e-05	0.00108	CcSEcCtD
Sunitinib—Infestation—Docetaxel—melanoma	3.89e-05	0.00108	CcSEcCtD
Sunitinib—PDGFRA—head—melanoma	3.88e-05	0.00109	CbGeAlD
Sunitinib—BMP2K—lymph node—melanoma	3.87e-05	0.00109	CbGeAlD
Sunitinib—CAMK2G—lymph node—melanoma	3.87e-05	0.00109	CbGeAlD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	3.87e-05	0.00107	CcSEcCtD
Sunitinib—Oedema—Carmustine—melanoma	3.86e-05	0.00107	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Docetaxel—melanoma	3.86e-05	0.00107	CcSEcCtD
Sunitinib—Decreased appetite—Bleomycin—melanoma	3.85e-05	0.00107	CcSEcCtD
Sunitinib—Infection—Carmustine—melanoma	3.84e-05	0.00106	CcSEcCtD
Sunitinib—Acute coronary syndrome—Docetaxel—melanoma	3.84e-05	0.00106	CcSEcCtD
Sunitinib—LRRK2—lymph node—melanoma	3.83e-05	0.00108	CbGeAlD
Sunitinib—Renal failure—Docetaxel—melanoma	3.83e-05	0.00106	CcSEcCtD
Sunitinib—Neuropathy peripheral—Docetaxel—melanoma	3.82e-05	0.00106	CcSEcCtD
Sunitinib—Dry mouth—Temozolomide—melanoma	3.81e-05	0.00106	CcSEcCtD
Sunitinib—Stomatitis—Docetaxel—melanoma	3.8e-05	0.00105	CcSEcCtD
Sunitinib—Pain—Bleomycin—melanoma	3.79e-05	0.00105	CcSEcCtD
Sunitinib—Thrombocytopenia—Carmustine—melanoma	3.78e-05	0.00105	CcSEcCtD
Sunitinib—PRKAA1—lymph node—melanoma	3.78e-05	0.00107	CbGeAlD
Sunitinib—Musculoskeletal discomfort—Dactinomycin—melanoma	3.76e-05	0.00104	CcSEcCtD
Sunitinib—PTK2B—lymph node—melanoma	3.74e-05	0.00105	CbGeAlD
Sunitinib—Oedema—Temozolomide—melanoma	3.73e-05	0.00103	CcSEcCtD
Sunitinib—FLT4—lymph node—melanoma	3.73e-05	0.00105	CbGeAlD
Sunitinib—Infection—Temozolomide—melanoma	3.71e-05	0.00103	CcSEcCtD
Sunitinib—Anorexia—Carmustine—melanoma	3.68e-05	0.00102	CcSEcCtD
Sunitinib—Hepatobiliary disease—Docetaxel—melanoma	3.68e-05	0.00102	CcSEcCtD
Sunitinib—CSNK1E—lymph node—melanoma	3.68e-05	0.00104	CbGeAlD
Sunitinib—FGFR1—lymph node—melanoma	3.68e-05	0.00104	CbGeAlD
Sunitinib—Epistaxis—Docetaxel—melanoma	3.67e-05	0.00102	CcSEcCtD
Sunitinib—Nervous system disorder—Temozolomide—melanoma	3.66e-05	0.00101	CcSEcCtD
Sunitinib—Thrombocytopenia—Temozolomide—melanoma	3.66e-05	0.00101	CcSEcCtD
Sunitinib—Skin disorder—Temozolomide—melanoma	3.63e-05	0.001	CcSEcCtD
Sunitinib—IRAK4—lymph node—melanoma	3.62e-05	0.00102	CbGeAlD
Sunitinib—Decreased appetite—Dactinomycin—melanoma	3.59e-05	0.000994	CcSEcCtD
Sunitinib—Fatigue—Dactinomycin—melanoma	3.56e-05	0.000986	CcSEcCtD
Sunitinib—Anorexia—Temozolomide—melanoma	3.56e-05	0.000986	CcSEcCtD
Sunitinib—ULK3—lymph node—melanoma	3.54e-05	0.000998	CbGeAlD
Sunitinib—MAP2K2—lymph node—melanoma	3.54e-05	0.000998	CbGeAlD
Sunitinib—Pain—Dactinomycin—melanoma	3.53e-05	0.000978	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Carmustine—melanoma	3.52e-05	0.000975	CcSEcCtD
Sunitinib—Haemoglobin—Docetaxel—melanoma	3.51e-05	0.000973	CcSEcCtD
Sunitinib—MAP3K2—lymph node—melanoma	3.51e-05	0.000991	CbGeAlD
Sunitinib—Body temperature increased—Bleomycin—melanoma	3.5e-05	0.000969	CcSEcCtD
Sunitinib—KDR—head—melanoma	3.5e-05	0.000987	CbGeAlD
Sunitinib—MAP2K5—head—melanoma	3.5e-05	0.000987	CbGeAlD
Sunitinib—Hepatitis—Docetaxel—melanoma	3.5e-05	0.000968	CcSEcCtD
Sunitinib—Haemorrhage—Docetaxel—melanoma	3.5e-05	0.000968	CcSEcCtD
Sunitinib—Insomnia—Carmustine—melanoma	3.49e-05	0.000968	CcSEcCtD
Sunitinib—MAP3K7—lymph node—melanoma	3.48e-05	0.000982	CbGeAlD
Sunitinib—Hypoaesthesia—Docetaxel—melanoma	3.48e-05	0.000963	CcSEcCtD
Sunitinib—Paraesthesia—Carmustine—melanoma	3.47e-05	0.000961	CcSEcCtD
Sunitinib—Urinary tract disorder—Docetaxel—melanoma	3.45e-05	0.000956	CcSEcCtD
Sunitinib—Dyspnoea—Carmustine—melanoma	3.44e-05	0.000954	CcSEcCtD
Sunitinib—Oedema peripheral—Docetaxel—melanoma	3.44e-05	0.000954	CcSEcCtD
Sunitinib—TBK1—lymph node—melanoma	3.44e-05	0.000971	CbGeAlD
Sunitinib—Connective tissue disorder—Docetaxel—melanoma	3.43e-05	0.000951	CcSEcCtD
Sunitinib—Urethral disorder—Docetaxel—melanoma	3.43e-05	0.000949	CcSEcCtD
Sunitinib—TYK2—lymph node—melanoma	3.42e-05	0.000964	CbGeAlD
Sunitinib—CSF1R—head—melanoma	3.41e-05	0.000963	CbGeAlD
Sunitinib—Musculoskeletal discomfort—Temozolomide—melanoma	3.4e-05	0.000942	CcSEcCtD
Sunitinib—Insomnia—Temozolomide—melanoma	3.38e-05	0.000935	CcSEcCtD
Sunitinib—Gastrointestinal pain—Dactinomycin—melanoma	3.38e-05	0.000935	CcSEcCtD
Sunitinib—IRAK1—lymph node—melanoma	3.37e-05	0.000952	CbGeAlD
Sunitinib—Decreased appetite—Carmustine—melanoma	3.36e-05	0.00093	CcSEcCtD
Sunitinib—Paraesthesia—Temozolomide—melanoma	3.35e-05	0.000929	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Carmustine—melanoma	3.34e-05	0.000924	CcSEcCtD
Sunitinib—Dyspnoea—Temozolomide—melanoma	3.33e-05	0.000922	CcSEcCtD
Sunitinib—RPS6KB1—lymph node—melanoma	3.31e-05	0.000934	CbGeAlD
Sunitinib—Erythema multiforme—Docetaxel—melanoma	3.3e-05	0.000915	CcSEcCtD
Sunitinib—Pain—Carmustine—melanoma	3.3e-05	0.000915	CcSEcCtD
Sunitinib—Constipation—Carmustine—melanoma	3.3e-05	0.000915	CcSEcCtD
Sunitinib—RET—lymph node—melanoma	3.29e-05	0.000928	CbGeAlD
Sunitinib—FGR—lymph node—melanoma	3.29e-05	0.000928	CbGeAlD
Sunitinib—Dyspepsia—Temozolomide—melanoma	3.29e-05	0.00091	CcSEcCtD
Sunitinib—AXL—lymph node—melanoma	3.28e-05	0.000924	CbGeAlD
Sunitinib—Eye disorder—Docetaxel—melanoma	3.27e-05	0.000905	CcSEcCtD
Sunitinib—Body temperature increased—Dactinomycin—melanoma	3.26e-05	0.000904	CcSEcCtD
Sunitinib—Abdominal pain—Dactinomycin—melanoma	3.26e-05	0.000904	CcSEcCtD
Sunitinib—Hypersensitivity—Bleomycin—melanoma	3.26e-05	0.000903	CcSEcCtD
Sunitinib—Decreased appetite—Temozolomide—melanoma	3.25e-05	0.000899	CcSEcCtD
Sunitinib—Cardiac disorder—Docetaxel—melanoma	3.24e-05	0.000898	CcSEcCtD
Sunitinib—Flushing—Docetaxel—melanoma	3.24e-05	0.000898	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Temozolomide—melanoma	3.22e-05	0.000893	CcSEcCtD
Sunitinib—Fatigue—Temozolomide—melanoma	3.22e-05	0.000892	CcSEcCtD
Sunitinib—Pain—Temozolomide—melanoma	3.19e-05	0.000884	CcSEcCtD
Sunitinib—Constipation—Temozolomide—melanoma	3.19e-05	0.000884	CcSEcCtD
Sunitinib—Asthenia—Bleomycin—melanoma	3.18e-05	0.00088	CcSEcCtD
Sunitinib—Angiopathy—Docetaxel—melanoma	3.17e-05	0.000878	CcSEcCtD
Sunitinib—Gastrointestinal pain—Carmustine—melanoma	3.16e-05	0.000875	CcSEcCtD
Sunitinib—Immune system disorder—Docetaxel—melanoma	3.16e-05	0.000874	CcSEcCtD
Sunitinib—SLK—lymph node—melanoma	3.15e-05	0.00089	CbGeAlD
Sunitinib—Mediastinal disorder—Docetaxel—melanoma	3.15e-05	0.000872	CcSEcCtD
Sunitinib—Chills—Docetaxel—melanoma	3.14e-05	0.000869	CcSEcCtD
Sunitinib—Pruritus—Bleomycin—melanoma	3.13e-05	0.000867	CcSEcCtD
Sunitinib—Arrhythmia—Docetaxel—melanoma	3.12e-05	0.000865	CcSEcCtD
Sunitinib—JAK2—lymph node—melanoma	3.11e-05	0.000877	CbGeAlD
Sunitinib—KIT—head—melanoma	3.1e-05	0.000874	CbGeAlD
Sunitinib—Alopecia—Docetaxel—melanoma	3.09e-05	0.000855	CcSEcCtD
Sunitinib—FYN—lymph node—melanoma	3.07e-05	0.000865	CbGeAlD
Sunitinib—Mental disorder—Docetaxel—melanoma	3.06e-05	0.000848	CcSEcCtD
Sunitinib—Body temperature increased—Carmustine—melanoma	3.05e-05	0.000846	CcSEcCtD
Sunitinib—Abdominal pain—Carmustine—melanoma	3.05e-05	0.000846	CcSEcCtD
Sunitinib—Gastrointestinal pain—Temozolomide—melanoma	3.05e-05	0.000846	CcSEcCtD
Sunitinib—Malnutrition—Docetaxel—melanoma	3.04e-05	0.000843	CcSEcCtD
Sunitinib—Erythema—Docetaxel—melanoma	3.04e-05	0.000843	CcSEcCtD
Sunitinib—Hypersensitivity—Dactinomycin—melanoma	3.04e-05	0.000842	CcSEcCtD
Sunitinib—PDGFRB—head—melanoma	3.03e-05	0.000854	CbGeAlD
Sunitinib—MAP4K5—lymph node—melanoma	3e-05	0.000845	CbGeAlD
Sunitinib—MAP3K3—lymph node—melanoma	3e-05	0.000845	CbGeAlD
Sunitinib—Dysgeusia—Docetaxel—melanoma	2.98e-05	0.000825	CcSEcCtD
Sunitinib—Asthenia—Dactinomycin—melanoma	2.96e-05	0.00082	CcSEcCtD
Sunitinib—Body temperature increased—Temozolomide—melanoma	2.95e-05	0.000817	CcSEcCtD
Sunitinib—Abdominal pain—Temozolomide—melanoma	2.95e-05	0.000817	CcSEcCtD
Sunitinib—Back pain—Docetaxel—melanoma	2.94e-05	0.000815	CcSEcCtD
Sunitinib—Muscle spasms—Docetaxel—melanoma	2.93e-05	0.00081	CcSEcCtD
Sunitinib—FLT1—lymph node—melanoma	2.9e-05	0.000817	CbGeAlD
Sunitinib—EPHB6—lymph node—melanoma	2.86e-05	0.000808	CbGeAlD
Sunitinib—Hypersensitivity—Carmustine—melanoma	2.85e-05	0.000788	CcSEcCtD
Sunitinib—Diarrhoea—Dactinomycin—melanoma	2.82e-05	0.000782	CcSEcCtD
Sunitinib—Vomiting—Bleomycin—melanoma	2.81e-05	0.000779	CcSEcCtD
Sunitinib—Anaemia—Docetaxel—melanoma	2.81e-05	0.000779	CcSEcCtD
Sunitinib—Rash—Bleomycin—melanoma	2.79e-05	0.000773	CcSEcCtD
Sunitinib—Dermatitis—Bleomycin—melanoma	2.79e-05	0.000772	CcSEcCtD
Sunitinib—ABCB1—blood vessel—melanoma	2.78e-05	0.000784	CbGeAlD
Sunitinib—Asthenia—Carmustine—melanoma	2.77e-05	0.000768	CcSEcCtD
Sunitinib—YES1—lymph node—melanoma	2.77e-05	0.000781	CbGeAlD
Sunitinib—Hypersensitivity—Temozolomide—melanoma	2.75e-05	0.000762	CcSEcCtD
Sunitinib—STK10—lymph node—melanoma	2.74e-05	0.000774	CbGeAlD
Sunitinib—TAOK3—lymph node—melanoma	2.73e-05	0.000771	CbGeAlD
Sunitinib—Leukopenia—Docetaxel—melanoma	2.72e-05	0.000754	CcSEcCtD
Sunitinib—PDGFRA—lymph node—melanoma	2.71e-05	0.000766	CbGeAlD
Sunitinib—Asthenia—Temozolomide—melanoma	2.68e-05	0.000742	CcSEcCtD
Sunitinib—Cough—Docetaxel—melanoma	2.65e-05	0.000735	CcSEcCtD
Sunitinib—Diarrhoea—Carmustine—melanoma	2.64e-05	0.000732	CcSEcCtD
Sunitinib—Pruritus—Temozolomide—melanoma	2.64e-05	0.000732	CcSEcCtD
Sunitinib—Convulsion—Docetaxel—melanoma	2.64e-05	0.00073	CcSEcCtD
Sunitinib—Nausea—Bleomycin—melanoma	2.63e-05	0.000728	CcSEcCtD
Sunitinib—Hypertension—Docetaxel—melanoma	2.63e-05	0.000727	CcSEcCtD
Sunitinib—Vomiting—Dactinomycin—melanoma	2.62e-05	0.000727	CcSEcCtD
Sunitinib—Rash—Dactinomycin—melanoma	2.6e-05	0.000721	CcSEcCtD
Sunitinib—Arthralgia—Docetaxel—melanoma	2.59e-05	0.000717	CcSEcCtD
Sunitinib—Chest pain—Docetaxel—melanoma	2.59e-05	0.000717	CcSEcCtD
Sunitinib—Myalgia—Docetaxel—melanoma	2.59e-05	0.000717	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	2.57e-05	0.000712	CcSEcCtD
Sunitinib—Dizziness—Carmustine—melanoma	2.56e-05	0.000708	CcSEcCtD
Sunitinib—Diarrhoea—Temozolomide—melanoma	2.55e-05	0.000708	CcSEcCtD
Sunitinib—Dry mouth—Docetaxel—melanoma	2.53e-05	0.000702	CcSEcCtD
Sunitinib—Oedema—Docetaxel—melanoma	2.48e-05	0.000688	CcSEcCtD
Sunitinib—Dizziness—Temozolomide—melanoma	2.47e-05	0.000684	CcSEcCtD
Sunitinib—Infection—Docetaxel—melanoma	2.47e-05	0.000683	CcSEcCtD
Sunitinib—Vomiting—Carmustine—melanoma	2.46e-05	0.00068	CcSEcCtD
Sunitinib—Nausea—Dactinomycin—melanoma	2.45e-05	0.000679	CcSEcCtD
Sunitinib—KDR—lymph node—melanoma	2.45e-05	0.000691	CbGeAlD
Sunitinib—MAP2K5—lymph node—melanoma	2.45e-05	0.000691	CbGeAlD
Sunitinib—Shock—Docetaxel—melanoma	2.44e-05	0.000677	CcSEcCtD
Sunitinib—Rash—Carmustine—melanoma	2.44e-05	0.000675	CcSEcCtD
Sunitinib—Nervous system disorder—Docetaxel—melanoma	2.44e-05	0.000674	CcSEcCtD
Sunitinib—Dermatitis—Carmustine—melanoma	2.43e-05	0.000674	CcSEcCtD
Sunitinib—Thrombocytopenia—Docetaxel—melanoma	2.43e-05	0.000673	CcSEcCtD
Sunitinib—Headache—Carmustine—melanoma	2.42e-05	0.00067	CcSEcCtD
Sunitinib—Skin disorder—Docetaxel—melanoma	2.41e-05	0.000668	CcSEcCtD
Sunitinib—ABCC4—head—melanoma	2.41e-05	0.00068	CbGeAlD
Sunitinib—CSF1R—lymph node—melanoma	2.39e-05	0.000674	CbGeAlD
Sunitinib—ABCG2—mammalian vulva—melanoma	2.38e-05	0.000671	CbGeAlD
Sunitinib—Vomiting—Temozolomide—melanoma	2.37e-05	0.000658	CcSEcCtD
Sunitinib—Anorexia—Docetaxel—melanoma	2.37e-05	0.000656	CcSEcCtD
Sunitinib—Rash—Temozolomide—melanoma	2.35e-05	0.000652	CcSEcCtD
Sunitinib—Dermatitis—Temozolomide—melanoma	2.35e-05	0.000651	CcSEcCtD
Sunitinib—Headache—Temozolomide—melanoma	2.34e-05	0.000648	CcSEcCtD
Sunitinib—Nausea—Carmustine—melanoma	2.3e-05	0.000636	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Docetaxel—melanoma	2.26e-05	0.000627	CcSEcCtD
Sunitinib—Insomnia—Docetaxel—melanoma	2.25e-05	0.000622	CcSEcCtD
Sunitinib—Paraesthesia—Docetaxel—melanoma	2.23e-05	0.000618	CcSEcCtD
Sunitinib—Nausea—Temozolomide—melanoma	2.22e-05	0.000614	CcSEcCtD
Sunitinib—Dyspnoea—Docetaxel—melanoma	2.21e-05	0.000613	CcSEcCtD
Sunitinib—Dyspepsia—Docetaxel—melanoma	2.19e-05	0.000605	CcSEcCtD
Sunitinib—KIT—lymph node—melanoma	2.17e-05	0.000612	CbGeAlD
Sunitinib—Decreased appetite—Docetaxel—melanoma	2.16e-05	0.000598	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Docetaxel—melanoma	2.14e-05	0.000594	CcSEcCtD
Sunitinib—Fatigue—Docetaxel—melanoma	2.14e-05	0.000593	CcSEcCtD
Sunitinib—Constipation—Docetaxel—melanoma	2.12e-05	0.000588	CcSEcCtD
Sunitinib—Pain—Docetaxel—melanoma	2.12e-05	0.000588	CcSEcCtD
Sunitinib—PDGFRB—lymph node—melanoma	2.12e-05	0.000598	CbGeAlD
Sunitinib—Gastrointestinal pain—Docetaxel—melanoma	2.03e-05	0.000562	CcSEcCtD
Sunitinib—Abdominal pain—Docetaxel—melanoma	1.96e-05	0.000544	CcSEcCtD
Sunitinib—Body temperature increased—Docetaxel—melanoma	1.96e-05	0.000544	CcSEcCtD
Sunitinib—KCNH2—head—melanoma	1.91e-05	0.00054	CbGeAlD
Sunitinib—Hypersensitivity—Docetaxel—melanoma	1.83e-05	0.000507	CcSEcCtD
Sunitinib—Asthenia—Docetaxel—melanoma	1.78e-05	0.000493	CcSEcCtD
Sunitinib—Pruritus—Docetaxel—melanoma	1.76e-05	0.000487	CcSEcCtD
Sunitinib—Diarrhoea—Docetaxel—melanoma	1.7e-05	0.000471	CcSEcCtD
Sunitinib—ABCC4—lymph node—melanoma	1.69e-05	0.000476	CbGeAlD
Sunitinib—Dizziness—Docetaxel—melanoma	1.64e-05	0.000455	CcSEcCtD
Sunitinib—ABCC2—lymph node—melanoma	1.63e-05	0.000461	CbGeAlD
Sunitinib—Vomiting—Docetaxel—melanoma	1.58e-05	0.000437	CcSEcCtD
Sunitinib—Rash—Docetaxel—melanoma	1.57e-05	0.000434	CcSEcCtD
Sunitinib—Dermatitis—Docetaxel—melanoma	1.56e-05	0.000433	CcSEcCtD
Sunitinib—Headache—Docetaxel—melanoma	1.56e-05	0.000431	CcSEcCtD
Sunitinib—Nausea—Docetaxel—melanoma	1.47e-05	0.000408	CcSEcCtD
Sunitinib—ABCB1—retina—melanoma	1.46e-05	0.000413	CbGeAlD
Sunitinib—KCNH2—lymph node—melanoma	1.34e-05	0.000378	CbGeAlD
Sunitinib—ABCG2—lymph node—melanoma	1.19e-05	0.000336	CbGeAlD
Sunitinib—ABCB1—mammalian vulva—melanoma	1.17e-05	0.000331	CbGeAlD
Sunitinib—ABCB1—head—melanoma	8.39e-06	0.000237	CbGeAlD
Sunitinib—ABCB1—lymph node—melanoma	5.87e-06	0.000166	CbGeAlD
Sunitinib—MAP2K1—Signaling Pathways—CCND1—melanoma	9.35e-08	1.2e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—NRAS—melanoma	9.34e-08	1.2e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—IL6—melanoma	9.34e-08	1.2e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—STAT3—melanoma	9.34e-08	1.2e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MYC—melanoma	9.34e-08	1.2e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—AKT1—melanoma	9.34e-08	1.2e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—NRAS—melanoma	9.32e-08	1.2e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—IL6—melanoma	9.32e-08	1.2e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—IL6—melanoma	9.32e-08	1.2e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—AKT1—melanoma	9.31e-08	1.2e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CTNNB1—melanoma	9.31e-08	1.2e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—HRAS—melanoma	9.29e-08	1.19e-06	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—AKT1—melanoma	9.26e-08	1.19e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CTNNB1—melanoma	9.26e-08	1.19e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MAPK1—melanoma	9.25e-08	1.19e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EGFR—melanoma	9.25e-08	1.19e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—AKT1—melanoma	9.25e-08	1.19e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CASP3—melanoma	9.18e-08	1.18e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MYC—melanoma	9.17e-08	1.18e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MYC—melanoma	9.17e-08	1.18e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL2—melanoma	9.16e-08	1.18e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—HRAS—melanoma	9.16e-08	1.18e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—PIK3CA—melanoma	9.14e-08	1.17e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PPARG—melanoma	9.14e-08	1.17e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MAPK1—melanoma	9.14e-08	1.17e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EGFR—melanoma	9.13e-08	1.17e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MMP9—melanoma	9.12e-08	1.17e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—IL6—melanoma	9.12e-08	1.17e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—IL6—melanoma	9.12e-08	1.17e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PRKCA—melanoma	9.12e-08	1.17e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—IL6—melanoma	9.12e-08	1.17e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—HRAS—melanoma	9.11e-08	1.17e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—IL6—melanoma	9.09e-08	1.17e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CDKN1A—melanoma	9.09e-08	1.17e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—PIK3CA—melanoma	9.09e-08	1.17e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—AKT1—melanoma	9.08e-08	1.17e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MMP9—melanoma	9.08e-08	1.17e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PTEN—melanoma	9.07e-08	1.17e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—AKT1—melanoma	9.07e-08	1.17e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ERCC2—melanoma	9.05e-08	1.16e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CDKN1A—melanoma	9.04e-08	1.16e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NFKB1—melanoma	9.03e-08	1.16e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PTEN—melanoma	9.02e-08	1.16e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KRAS—melanoma	9e-08	1.16e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—HRAS—melanoma	8.99e-08	1.16e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NFKB1—melanoma	8.98e-08	1.15e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MAPK1—melanoma	8.97e-08	1.15e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MAPK1—melanoma	8.97e-08	1.15e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EGFR—melanoma	8.97e-08	1.15e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EGFR—melanoma	8.97e-08	1.15e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MAPK3—melanoma	8.95e-08	1.15e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCND1—melanoma	8.93e-08	1.15e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MAPK3—melanoma	8.93e-08	1.15e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—IL6—melanoma	8.89e-08	1.14e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CTNNB1—melanoma	8.85e-08	1.14e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP17A1—melanoma	8.81e-08	1.13e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—AKT1—melanoma	8.8e-08	1.13e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—HRAS—melanoma	8.77e-08	1.13e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—IL6—melanoma	8.77e-08	1.13e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTEN—melanoma	8.75e-08	1.12e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KRAS—melanoma	8.74e-08	1.12e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—AKT1—melanoma	8.74e-08	1.12e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—IL6—melanoma	8.72e-08	1.12e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—PIK3CA—melanoma	8.72e-08	1.12e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—VEGFA—melanoma	8.71e-08	1.12e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—HRAS—melanoma	8.71e-08	1.12e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MYC—melanoma	8.7e-08	1.12e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—PIK3CA—melanoma	8.69e-08	1.12e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MYC—melanoma	8.68e-08	1.12e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—AKT1—melanoma	8.68e-08	1.12e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MMP9—melanoma	8.67e-08	1.12e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTEN—melanoma	8.67e-08	1.12e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CDKN1A—melanoma	8.64e-08	1.11e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KRAS—melanoma	8.63e-08	1.11e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—STAT3—melanoma	8.63e-08	1.11e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PTEN—melanoma	8.62e-08	1.11e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—AKT1—melanoma	8.62e-08	1.11e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—NRAS—melanoma	8.6e-08	1.11e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—IL6—melanoma	8.6e-08	1.11e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—AKT1—melanoma	8.6e-08	1.11e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—AKT1—melanoma	8.6e-08	1.11e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NFKB1—melanoma	8.58e-08	1.1e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MAPK1—melanoma	8.51e-08	1.09e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EGFR—melanoma	8.51e-08	1.09e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—VEGFA—melanoma	8.5e-08	1.09e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MAPK1—melanoma	8.49e-08	1.09e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EGFR—melanoma	8.49e-08	1.09e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KRAS—melanoma	8.47e-08	1.09e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—KRAS—melanoma	8.47e-08	1.09e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—HRAS—melanoma	8.46e-08	1.09e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—melanoma	8.43e-08	1.08e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—AKT1—melanoma	8.42e-08	1.08e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—STAT3—melanoma	8.42e-08	1.08e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—AKT1—melanoma	8.42e-08	1.08e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—AKT1—melanoma	8.41e-08	1.08e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—HRAS—melanoma	8.41e-08	1.08e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—NRAS—melanoma	8.4e-08	1.08e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—IL6—melanoma	8.4e-08	1.08e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—AKT1—melanoma	8.39e-08	1.08e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—IL6—melanoma	8.33e-08	1.07e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CD—melanoma	8.32e-08	1.07e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GNA11—melanoma	8.32e-08	1.07e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—PIK3CA—melanoma	8.27e-08	1.06e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MAPK3—melanoma	8.24e-08	1.06e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—ALB—melanoma	8.22e-08	1.06e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—AKT1—melanoma	8.2e-08	1.05e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—VEGFA—melanoma	8.19e-08	1.05e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—VEGFA—melanoma	8.15e-08	1.05e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—FASN—melanoma	8.14e-08	1.05e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—STAT3—melanoma	8.11e-08	1.04e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NRAS—melanoma	8.09e-08	1.04e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—IL6—melanoma	8.09e-08	1.04e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—AKT1—melanoma	8.09e-08	1.04e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—STAT3—melanoma	8.07e-08	1.04e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—HRAS—melanoma	8.07e-08	1.04e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NRAS—melanoma	8.05e-08	1.03e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—IL6—melanoma	8.05e-08	1.03e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—AKT1—melanoma	8.04e-08	1.03e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KRAS—melanoma	8.04e-08	1.03e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MAPK3—melanoma	8.04e-08	1.03e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—HRAS—melanoma	8.04e-08	1.03e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—PIK3CA—melanoma	8.03e-08	1.03e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KRAS—melanoma	8.02e-08	1.03e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MYC—melanoma	8.01e-08	1.03e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—SLC5A5—melanoma	8.01e-08	1.03e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—melanoma	8e-08	1.03e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—AKT1—melanoma	7.94e-08	1.02e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—PIK3CA—melanoma	7.93e-08	1.02e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MAPK1—melanoma	7.84e-08	1.01e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EGFR—melanoma	7.84e-08	1.01e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MYC—melanoma	7.82e-08	1.01e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—VEGFA—melanoma	7.79e-08	1e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—PIK3CA—melanoma	7.79e-08	1e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—PIK3CA—melanoma	7.79e-08	1e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—melanoma	7.77e-08	9.98e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MAPK3—melanoma	7.75e-08	9.97e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—AKT1—melanoma	7.75e-08	9.96e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GNAQ—melanoma	7.73e-08	9.94e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CD44—melanoma	7.73e-08	9.94e-07	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—IL6—melanoma	7.72e-08	9.92e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—STAT3—melanoma	7.71e-08	9.91e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MAPK3—melanoma	7.71e-08	9.91e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NRAS—melanoma	7.69e-08	9.89e-07	CbGpPWpGaD
Sunitinib—JAK2—Disease—IL6—melanoma	7.69e-08	9.89e-07	CbGpPWpGaD
Sunitinib—JAK2—Immune System—AKT1—melanoma	7.69e-08	9.88e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—melanoma	7.67e-08	9.86e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MAPK1—melanoma	7.65e-08	9.84e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EGFR—melanoma	7.65e-08	9.84e-07	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—HRAS—melanoma	7.65e-08	9.84e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MYC—melanoma	7.54e-08	9.69e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—melanoma	7.53e-08	9.68e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—melanoma	7.53e-08	9.68e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MYC—melanoma	7.5e-08	9.64e-07	CbGpPWpGaD
Sunitinib—FYN—Disease—AKT1—melanoma	7.47e-08	9.6e-07	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—HRAS—melanoma	7.43e-08	9.55e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—AKT1—melanoma	7.43e-08	9.55e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP1B1—melanoma	7.42e-08	9.53e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KRAS—melanoma	7.41e-08	9.52e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—PIK3CA—melanoma	7.39e-08	9.5e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MAPK1—melanoma	7.38e-08	9.48e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EGFR—melanoma	7.37e-08	9.48e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—PIK3CA—melanoma	7.37e-08	9.47e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MAPK3—melanoma	7.37e-08	9.47e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MAPK1—melanoma	7.34e-08	9.43e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EGFR—melanoma	7.33e-08	9.43e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—HRAS—melanoma	7.33e-08	9.43e-07	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—IL6—melanoma	7.32e-08	9.41e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CB—melanoma	7.26e-08	9.33e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KRAS—melanoma	7.23e-08	9.29e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HRAS—melanoma	7.2e-08	9.26e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HRAS—melanoma	7.2e-08	9.26e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTGS2—melanoma	7.19e-08	9.24e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MYC—melanoma	7.17e-08	9.21e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—melanoma	7.15e-08	9.19e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CG—melanoma	7.14e-08	9.19e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—melanoma	7.13e-08	9.17e-07	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—AKT1—melanoma	7.12e-08	9.16e-07	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IL6—melanoma	7.11e-08	9.14e-07	CbGpPWpGaD
Sunitinib—JAK2—Disease—AKT1—melanoma	7.1e-08	9.12e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IL6—melanoma	7.02e-08	9.02e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MAPK1—melanoma	7.01e-08	9.01e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EGFR—melanoma	7.01e-08	9.01e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KRAS—melanoma	6.97e-08	8.96e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KRAS—melanoma	6.93e-08	8.91e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PPARG—melanoma	6.9e-08	8.87e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IL6—melanoma	6.89e-08	8.86e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IL6—melanoma	6.89e-08	8.86e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HRAS—melanoma	6.84e-08	8.79e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HRAS—melanoma	6.82e-08	8.77e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PIK3CA—melanoma	6.8e-08	8.75e-07	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—AKT1—melanoma	6.75e-08	8.68e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PIK3CA—melanoma	6.64e-08	8.54e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KRAS—melanoma	6.62e-08	8.51e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—melanoma	6.58e-08	8.46e-07	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—AKT1—melanoma	6.56e-08	8.43e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IL6—melanoma	6.54e-08	8.41e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IL6—melanoma	6.53e-08	8.39e-07	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—AKT1—melanoma	6.48e-08	8.33e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—melanoma	6.42e-08	8.26e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PIK3CA—melanoma	6.4e-08	8.23e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PIK3CA—melanoma	6.37e-08	8.18e-07	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—AKT1—melanoma	6.36e-08	8.18e-07	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—AKT1—melanoma	6.36e-08	8.18e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HRAS—melanoma	6.29e-08	8.09e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CD—melanoma	6.28e-08	8.08e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTEN—melanoma	6.27e-08	8.06e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ALB—melanoma	6.2e-08	7.97e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—melanoma	6.19e-08	7.96e-07	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PIK3CA—melanoma	6.17e-08	7.94e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—melanoma	6.16e-08	7.92e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HRAS—melanoma	6.14e-08	7.9e-07	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PIK3CA—melanoma	6.12e-08	7.87e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ABCB1—melanoma	6.11e-08	7.85e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PIK3CA—melanoma	6.08e-08	7.82e-07	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—AKT1—melanoma	6.04e-08	7.76e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IL6—melanoma	6.02e-08	7.75e-07	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—AKT1—melanoma	6.02e-08	7.74e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HRAS—melanoma	5.92e-08	7.61e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HRAS—melanoma	5.89e-08	7.57e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—melanoma	5.89e-08	7.57e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IL6—melanoma	5.88e-08	7.56e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IL6—melanoma	5.67e-08	7.29e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL6—melanoma	5.64e-08	7.25e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HRAS—melanoma	5.63e-08	7.24e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PRKCA—melanoma	5.62e-08	7.23e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ERCC2—melanoma	5.57e-08	7.17e-07	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—AKT1—melanoma	5.56e-08	7.15e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CB—melanoma	5.47e-08	7.04e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTGS2—melanoma	5.42e-08	6.97e-07	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—AKT1—melanoma	5.42e-08	6.97e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL6—melanoma	5.39e-08	6.93e-07	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—AKT1—melanoma	5.23e-08	6.72e-07	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—AKT1—melanoma	5.2e-08	6.69e-07	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—AKT1—melanoma	5.04e-08	6.48e-07	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—AKT1—melanoma	5e-08	6.43e-07	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—AKT1—melanoma	4.97e-08	6.39e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTEN—melanoma	4.73e-08	6.08e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CA—melanoma	4.42e-08	5.69e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CG—melanoma	4.4e-08	5.66e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PPARG—melanoma	4.25e-08	5.46e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CD—melanoma	3.87e-08	4.98e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ALB—melanoma	3.82e-08	4.91e-07	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—AKT1—melanoma	3.61e-08	4.65e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CB—melanoma	3.37e-08	4.34e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS2—melanoma	3.34e-08	4.3e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CA—melanoma	3.34e-08	4.29e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTEN—melanoma	2.91e-08	3.75e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—AKT1—melanoma	2.73e-08	3.51e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CA—melanoma	2.06e-08	2.64e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AKT1—melanoma	1.68e-08	2.16e-07	CbGpPWpGaD
